Eidogen-Sertanty, Inc. has announced that they have established collaboration with San Diego-based Kalypsys, Inc, focused on the discovery of small molecules for anti-inflammatory indications.
Under the terms of the collaboration, Eidogen-Sertanty will utilize its DirectDesign™ computational drug discovery platform to design a virtual library of synthetically tractable and drug-like compounds with predicted activity against a target of interest to Kalypsys.
The collaboration builds upon Kalypsys’ existing relationship with Eidogen-Sertanty as a customer of the Target Informatics Platform™ (TIP™).
"The team at Eidogen-Sertanty believes that our expertise in targeted library design will help deliver leads for Kalypsys’ small molecule pipeline," said Dr. Steve Muskal, CEO of Eidogen-Sertanty.
"We are pleased to partner with Eidogen-Sertanty. Their technology appears to have great potential and we look forward to applying it to this research effort," stated Stewart Noble, VP of Chemistry at Kalypsys.